menu
    • menu

    Company profile for Sichuan Kelun-Biotech Biopharmaceutical

    NEW Drugs in Dev: 16
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. focuses on research, development, and manufacturing of biopharmaceutical products. With expertise in innovative drug development, clinical trials, and large-scale manufacturing, Kelun-Biotech aims to provide advanced therapeutic solutions. Their platforms support new drug research, quality manufacturing, and global commercialization.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sichuan Kelun-Biotech BiopharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    No. 666 Xinhua Avenue Chengdu Cross-Strait Science and Technology Industry Dev...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://en.kelun-biotech.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kelun, Merck's Lung Cancer Combo Boosts Late-Stage Survival
    Kelun, Merck's Lung Cancer Combo Boosts Late-Stage Survival

    22 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/kelun-mercks-lung-cancer-combo-improves-survival-late-stage-china-trial-2026-05-21/

    REUTERS
    22 May 2026
    Share Share
    Kelun-Biotech To Present Lung Cancer Studies At ASCO 2026
    Kelun-Biotech To Present Lung Cancer Studies At ASCO 2026

    22 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-to-present-two-registrational-studies-in-the-oral-presentation-session-on-non-small-cell-lung-cancer-at-asco-2026-302779211.html

    PR NEWSWIRE
    22 May 2026
    Share Share
    Merck's Kelun TROP2 Bet Pays Off in Endometrial Cancer
    Merck's Kelun TROP2 Bet Pays Off in Endometrial Cancer

    19 May 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/mercks-billion-dollar-kelun-bet-pays-off-as-trop2-improves-survival-in-endometrial-cancer

    BIOSPACE
    19 May 2026
    Share Share
    China NMPA Accepts sac-TMT Plus Pembro sNDA in PD-L1+ NSCLC
    China NMPA Accepts sac-TMT Plus Pembro sNDA in PD-L1+ NSCLC

    08 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/the-snda-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-as-firstline-treatment-for-pd-l1-positive-nsclc-accepted-for-review-by-nmpa-302766841.html

    PR NEWSWIRE
    08 May 2026
    Share Share
    HKEX Approves Kelun-Biotech to Drop 'B' from Stock Code
    HKEX Approves Kelun-Biotech to Drop 'B' from Stock Code

    09 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-approved-by-hkex-to-remove-b-marker-from-stock-code-representing-a-new-stage-of-development-302738138.html

    PR NEWSWIRE
    09 Apr 2026
    Share Share
    Kelun-Biotech Receives IND Approval for SKB103, Bispecific ADC
    Kelun-Biotech Receives IND Approval for SKB103, Bispecific ADC

    24 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-receives-ind-approval-for-skb103-a-novel-taa-pd-l1-bispecific-adc-302723140.html

    PR NEWSWIRE
    24 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search